2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1104

A Genome-Wide Association Study of Gout in People of European Ancestry
Abstract Number: 2343

A Genome-Wide Association Study Suggests the HLA Class II Region As the Major Susceptibility Locus for IgA Vasculitis
Abstract Number: 938

A Germline Macrophage Activation Syndrome-Associated Nlrc4 Mutation Causes Chronic, Systemic, Non-Hematopoietic IL-18 Elevation and Intestinal MHC-II Upregulation
Abstract Number: 2828

A Graph-Theoretic-Approach Applied to Modular-Repertoire-Analysis Identifies Shared Gradual Whole Blood Interferon Signatures in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome Patients and Reveals New Interferon-Related Modules in Disease Progression
Abstract Number: 1474

A Higher DAS28P, the Subjective Proportion of the DAS28, Predicts a Favorable Response to Abatacept in Rheumatoid Arthritis
Abstract Number: 1647

A Lupus Low Disease Activity State Is Associated with Reduced Flare, Lower Organ Damage Accrual, and Better Quality of Life in Patients with Systemic Lupus Erythematosus
Abstract Number: 451

A Matrix Risk Model for Prediction of Radiographic Progression in Early Rheumatoid Arthritis Based on Treatment Response at 3 Months
Abstract Number: 321

A Meta-Analysis of 4 Clinical Trials of Denosumab Compared with Bisphosphonates in Postmenopausal Women Previously Treated with Oral Bisphosphonates
Abstract Number: 2212

A Metabolite of C-Reactive Protein, a Marker of Disease Actvity, Is Prognostic of Radiographic Knee OA
Abstract Number: 1567

A Mitogen-Associated Protein Kinase (MAPK) Associated Kinase 2 Inhibitor Decreases in Vitro Th17 and Monocyte Inflammatory Responses in Spondyloarthritis
Abstract Number: 1094

A Model for Improved Management of Fragility Fractures: Navigating the Fracture Liaison Service
Abstract Number: 296

A Module of Genes Describing Low Density Granulocytes Can be Identified and Followed in the Periphery of Lupus Patients
Abstract Number: 1179

A Multi-Organ Inflammatory Condition with Features of Idiopathic Multicentric Castleman’s Disease and IgG4-Related Disease: An Unrecognized Mimicker of IgG4-RD
Abstract Number: 1589

A Multicriteria Decision Analysis for the Development of New Systemic Lupus Erythematosus Classification Criteria
Abstract Number: 1090

A Multidisciplinary Performance Improvement Approach to Achieving Goal Serum Uric Acid Levels in Patients with Gout

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].